Elite Pharmaceuticals Inc. (ELTP)
OTCQB OTCQB Primary 
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2025 Financial Results on November 15, 2024
Financials for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 will be released on Thursday, November 14, 2024 Northvale, New Jersey--(Newsfile Corp. - November 7, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the second quarter financial results of the 2025 fiscal year will be released on Thursday, November 14, 2024. Elite's management will host a live conference call on Friday, November 15th, at 11:30 AM EST to discuss the company's financial and operating results and provide a general business update.
Elite Pharmaceuticals Announces Commercial Launch of Generic Methotrexate Sodium
Northvale, New Jersey--(Newsfile Corp. - August 27, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic methotrexate sodium 2.5 mg tablets. Methotrexate sodium tablets are a dihydrofolate reductase inhibitor indicated for the: Treatment of adults with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen, mycosis fungoides, relapsed or refractory non-Hodgkin's lymphoma as part of a metronomic combination regimen, rheumatoid arthritis and severe psoriasis Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) and acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen This product is marketed and sold under the Elite Laboratories, Inc. label.
Elite Pharmaceuticals (ELTP) Posts Breakeven Q1 Earnings
Strength in Elite Pharmaceuticals' (ELTP) Manufacturing fees drive its fiscal first-quarter performance.
Elite Pharmaceuticals, Inc. (ELTP) Q1 2025 Earnings Call Transcript
Elite Pharmaceuticals, Inc. (OTCQB:ELTP) Q1 2025 Earnings Conference Call August 15, 2024 11:30 AM ET Company Participants Nasrat Hakim – President and Chief Executive Officer Carter Ward – Chief Financial Officer Conference Call Participants Operator Good morning, ladies and gentlemen, and welcome to the Elite Pharmaceuticals First Quarter of Fiscal Year 2025 Conference Call. At this time, all lines have been placed on a listen-only mode.
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2025 Ended June 30, 2024 and Provides Conference Call Information
Conference Call Scheduled for Thursday, August 15 at 11:30 AM EDT Northvale, New Jersey--(Newsfile Corp. - August 14, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the three months ended June 30, 2024, which is the first quarter of the Company's fiscal year ending on March 31, 2025 ("First Quarter"). Consolidated revenues for the three-month period ended June 30, 2024, were $18.8 million, an increase of $9.8 million or approximately 109% as compared to the comparable period of the prior fiscal year.
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2025 Financial Results on August 15, 2024
Financials for First Quarter of Fiscal Year 2025 Ended June 30, 2024 will be released on August 14, 2024 Northvale, New Jersey--(Newsfile Corp. - August 9, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the first quarter financial results of the 2025 fiscal year will be released on Wednesday, August 14, 2024. Elite's management will host a live conference call on Thursday, August 15th, at 11:30 AM EDT to discuss the company's financial and operating results and provide a general business update.
Zacks Initiates Coverage of Elite Pharmaceuticals With Outperform Recommendation
Discover why Zacks rates Elite Pharmaceuticals as "Outperform", being the first on Wall Street to initiate coverage on the stock. Explore ELTP's strategic partnerships, financial health, and robust product pipeline.
Elite Pharmaceuticals, Inc. (ELTP) Q4 2024 Earnings Call Transcript
Elite Pharmaceuticals, Inc. (OTCQB:ELTP) Q4 2024 Earnings Conference Call July 2, 2024 11:30 AM ET Company Participants Nasrat Hakim - President and CEO Carter Ward - CFO, Secretary and Treasurer Conference Call Participants Operator Good morning, ladies and gentlemen, and welcome to the Elite Pharmaceuticals Conference Call. At this time, all lines have been placed on a listen-only mode.
Elite Pharmaceuticals' (ELTP) FY24 Earnings Up, Gross Margin Down
Elite Pharmaceuticals' (ELTP) overall top line benefits from revenue growth in Manufacturing fees.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Conference Call Information
Conference Call Scheduled for Tuesday, July 2 at 11:30 AM EDT Northvale, New Jersey--(Newsfile Corp. - July 1, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2024 ("Fiscal 2024"). Consolidated revenues for Fiscal 2024 were $56.6 million, an increase of $22.4 million or approximately 65% as compared to the comparable period of the prior fiscal year.
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2024 Financial Results on July 2, 2024
Financials for Fiscal Year 2024 Ended March 31, 2024 will be released on July 1, 2024 Northvale, New Jersey--(Newsfile Corp. - June 26, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that it would release its 2024 fiscal year-end financial results on Monday, July 1, 2024. Elite's management will host a live conference call on Tuesday, July 2nd, at 11:30 AM EDT to discuss the company's financial and operating results and provide a general business update.
Elite Pharmaceuticals Receives FDA Approval for Generic Methotrexate
NORTHVALE, NJ / ACCESSWIRE / May 20, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for generic Methotrexate Sodium 2.5 mg tablets. Methotrexate belongs to a class of drugs known as antimetabolites and will be sold under the Elite Laboratories, Inc. label.
